In the former report, therapeutic co-administration of anti-TGF-β and anti-PD-L1 mAbs was found to reduce TGF-β signaling in stromal cells such as fibroblasts and increase penetration of CD8+ T cells into EMT6 tumors, thus provoking anti-tumor immunity and tumor regression35. This evidence concerns the gene TGFB1 and neoplasm.